Yüklüyor......
Hydroxyurea down-regulates BCL11A, KLF-1 and MYB through miRNA-mediated actions to induce γ-globin expression: implications for new therapeutic approaches of sickle cell disease
BACKGROUND: The major therapeutic benefit of hydroxyurea, the only FDA-approved pharmacologic treatment for sickle cell disease (SCD), is directly related to fetal hemoglobin (HbF) production that leads to significant reduction of morbidity and mortality. However, potential adverse effects such as i...
Kaydedildi:
| Yayımlandı: | Clin Transl Med |
|---|---|
| Asıl Yazarlar: | , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Springer Berlin Heidelberg
2016
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4824700/ https://ncbi.nlm.nih.gov/pubmed/27056246 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40169-016-0092-7 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|